Drugs / Allogeneic Mesenchymal Stromal Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03042572 | Dec 2018 → Dec 2020 | peripheral arterial disease | Martin Teraa, MD, PhD | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Stromal Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03042572 ↗ |
| Modality | Cell therapy | “Mesenchymal stromal cells (MSCs), because of their vasculoregenerative and immunomodulatory characteristics, have emerged as a potential new treatment.” PMID 29242062 ↗ Dec 2017 |